Company provides updates on recent developments and highlights plans for future growth
Santa Monica, CA, Feb. 12, 2019 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the Company has issued their February 2019 letter to its shareholders, highlighting their recent uplisting to the Nasdaq Capital Market, commercialization efforts, their relationships with world renowned medical centers and strategic goals moving forward.
Recent Company Highlights
- Uplisted shares of the company’s common stock to the Nasdaq Capital Market, under the ticker “BSGM”.
- Successfully raised a total of $13.5 million of capital, to finance upcoming operational milestones.
- Received a ‘Buy’ rating with $14.00/share price target from ROTH Capital Partners.
- Formed an Advisory Board to complement our existing Board of Directors and advise the Company leadership on a range of subjects, including financing, commercialization, government affairs and strategic partnerships.
- Announced that the company will be presenting the results from the First-in-Human studies and the early feedback from the use of its PURE EP(tm) System to a larger community of physicians, and other potential customers, in May 2019.
“As BioSig moves towards commercialization of our proprietary PURE EP(tm) System, we believe that now is an ideal time to update investors on the recent achievements the Company has made in establishing a platform capable of sustaining long-term growth,” stated Mr. Kenneth Londoner, Founder, Chairman and CEO of BioSig Technologies. “The Company has fortified its balance sheet, uplisted to a more senior exchange, and expanded strategic relationships with some of the most recognizable names in the medical technology sector. We are at a key inflection point in the company’s growth trajectory and anticipate that 2019 will be a very significant year for us. We are well-positioned to execute on our early commercialization strategy and improve overall shareholder value.”
To view BioSig Technologies’ Shareholder Letter please visit the Company’s website.
About BioSig Technologies
BioSig Technologies is a medical technology company developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace (www.biosig.com). Led by a proven management team and a veteran Board of Directors, BioSig Technologies is preparing to commercialize its PURE EP™ System. The technology has been developed to address an unmet need in a large and growing market.
The Company’s first product, PURE EP™ System, is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision-making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018.
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
CONTACT: Contact: Natasha Drapeau BioSig Technologies, Inc. Executive Vice President 12424 Wilshire Blvd Ste 745 Los Angeles, CA 90025 firstname.lastname@example.org 310-620-9320